The new prefilled syringe has the same composition but removes the need for reconstitution, providing a more convenient option for health care providers who administer vaccines. According to the ...

The prefilled syringes market has become a vital segment within the healthcare industry, combining efficiency and safety in medication delivery. As healthcare evolves, the growing demand for ...

Avery Dennison, in partnership with Turck Vilant Systems & Becton, Dickinson and Company, introduces BD iDFill Individual ...

MENTOR, Ohio — January 16, 2025 — Avery Dennison has announced its plans for Pharmapack 2025, which includes showcasing a groundbreaking RFID (radio frequency identification) pre-filled syringe (PFS) ...

The differences between PFSs and MDVs (per 1000 doses) is 324.21. MDV: Multidose vial; NA: Not available; PFS: Prefilled syringe. Prefilled syringes (PFSs) have gained market share in the USA ...

The functional label wraps around the syringe barrel and cap like a second skin, offering an irreversible first-opening indication that is automatically activated when the cap is opened. This approach ...

Skyrizi was the top Rx and over-the-counter (OTC) pharma brand advertising on TV in 2024, according to data released by iSpot.tv on Thursday afternoon. AbbVie’s psoriasis, ulcerative colitis, Crohn’s ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

SAE Media Group's 15th Annual Pre-Filled Syringes and Injectable Drug Devices Conference 2023 will be bigger than ever, with a pre-conference focus day exploring the advances in PFS design for ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...